Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does BASILIXIMAB Cause Blindness unilateral? 7 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Blindness unilateral have been filed in association with BASILIXIMAB (Simulect). This represents 0.1% of all adverse event reports for BASILIXIMAB.

7
Reports of Blindness unilateral with BASILIXIMAB
0.1%
of all BASILIXIMAB reports
0
Deaths
6
Hospitalizations

How Dangerous Is Blindness unilateral From BASILIXIMAB?

Of the 7 reports, 6 (85.7%) required hospitalization, and 4 (57.1%) were considered life-threatening.

Is Blindness unilateral Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for BASILIXIMAB. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does BASILIXIMAB Cause?

Cytomegalovirus infection (590) Drug ineffective (567) Off label use (567) Transplant rejection (554) Kidney transplant rejection (456) Product use in unapproved indication (428) Pyrexia (323) Diarrhoea (314) Multiple organ dysfunction syndrome (298) Polyomavirus-associated nephropathy (298)

What Other Drugs Cause Blindness unilateral?

AFLIBERCEPT (1,012) ADALIMUMAB (831) INSULIN GLARGINE (285) INTERFERON BETA-1A (275) RANIBIZUMAB (274) DIMETHYL (272) INSULIN LISPRO (267) TOCILIZUMAB (215) NATALIZUMAB (168) BEVACIZUMAB (165)

Which BASILIXIMAB Alternatives Have Lower Blindness unilateral Risk?

BASILIXIMAB vs BAYER GENUINE ASPIRIN ORIGINAL STRENGTH BASILIXIMAB vs BAZEDOXIFENE\ESTROGENS, CONJUGATED BASILIXIMAB vs BCG VACCINE BASILIXIMAB vs BEBTELOVIMAB BASILIXIMAB vs BECLOMETHASONE

Related Pages

BASILIXIMAB Full Profile All Blindness unilateral Reports All Drugs Causing Blindness unilateral BASILIXIMAB Demographics